GlassScriptPhysician profile
Robert O Schiftan
NPI 1215063839
$4,373.17
in general payments reported to CMS, 2019-2025
23 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $241 · 2021: $896 · 2022: $462 · 2023: $540 · 2024: $376 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,039.49 | 2019-2025 | Nuplazid |
| Abbvie INC. | $743.31 | 2022-2025 | Ubrelvy, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $365.83 | 2021-2025 | Zeposia |
| Argenx US, INC. | $297.76 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $280.14 | 2021-2022 | |
| Lilly USA, LLC | $247.55 | 2024-2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $241.01 | 2021 | |
| Abbott Laboratories | $180.19 | 2025 | Amplatzer Amulet |
| Janssen Pharmaceuticals, INC | $137.57 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $125.00 | 2025 | Inbrija |
| Janssen Biotech, INC. | $119.81 | 2025 | |
| Harmony Biosciences LLC | $117.27 | 2021 | |
| Mdd US Operations, LLC | $105.84 | 2019-2022 | |
| Kyowa Kirin, INC. | $83.02 | 2022 | |
| Ucb, INC. | $73.24 | 2025 | Rystiggo, Zilbrysq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $46.25 | 2024 | Pocket Eeg Device |
| Biohaven Pharmaceutical Holding Company LTD. | $39.38 | 2022 | |
| Biogen, INC. | $36.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.02 | 2019 | |
| Neurelis, INC. | $17.92 | 2021 | |
| Eisai INC. | $17.31 | 2021 | |
| Allergan, INC. | $16.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schiftan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.